NCT01318525Unknown2 期
A Multicentre, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and the Safety of ALF-5755 in Patients With Nonacetaminophen Severe Acute Hepatitis and Early Stage Acute Liver Failure
Alfact Innovation12 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2010年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 60
- 试验地点
- 12
- 主要终点
- Rate of change of Prothrombin Rate initiation
研究概览
简要总结
Acute liver failure is a rare but dramatic disease, often affecting young people, marked by the sudden loss of liver function in a person without preexisting liver disease.
ALF-5755 has been shown to promote cell survival after apoptotic or oxidative stress, and liver cell regeneration in primary cultures and in vivo. ALF-5755 may become, in this dramatic disease with high unmet medical need, a future therapy for the treatment of patients suffering from severe acute hepatitis (SAH) and acute liver failure (ALF) not due to acetaminophen overdose, where liver transplantation is the sole treatment in the absence of spontaneous recovery.
The primary objective of the study is to evaluate the efficacy of ALF-5755 versus placebo.
A minimum of 60 patients will be recruited into the study in the following two treatment groups:
- Group A: approximately 30 patients will receive ALF-5755
- Group B: approximately 30 patients will receive placebo (physiological saline solution: 0.9% NaCl)
Patients will receive 10 mg (25 ml) of ALF5755 or placebo every 12 hours over 3 days in slow intravenous infusions over 10 minutes using automatic syringes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A signed written informed consent from patient or from patient's next of kin or from an authorized person according to local procedures
- •Early stage acute liver failure OR severe acute hepatitis defined as:
- •15% ≤ PR < 50%
- •No hepatic encephalopathy, OR grade I or II encephalopathy (Appendix E)
- •Presumed acute illness onset of less than 26 weeks
- •No evidence of underlying chronic liver disease
- •Patient who can receive first treatment dose within the first 48 hours after biological baseline assessment
- •Age ≥ 18 and ≤ 65 years
- •Contraception (only for females of childbearing potential) to be taken throughout the study until D
- •Sole mechanic contraceptives, such as condoms, are advised. Note: Oral contraceptives may have contraindications in case of severe acute hepatitis and acute liver failure
- •Patient affiliated to social security insurance system.
排除标准
- •Acetaminophen-induced hepatitis defined as acetaminophen intake > 4 g/day, at least once in the 7 days prior to baseline
- •Shock liver (ischemic hepatopathy) OR HELLP syndrome OR Budd-Chiari syndrome OR intrahepatic malignancy
- •Serum creatinine ≥ 180 μmol/L
- •Body Mass Index (BMI) ≥ 35
- •Septic shock requiring administration of inotropic drugs
- •Uncontrolled active bleeding
- •Patients who received fresh frozen plasma, PPSB (Prothrombin-Proconvertin-Stuart-B), or vitamin K infusion over the last 48 hours
- •Patient receiving liver support device treatment, including but not exclusively bioartificial liver (BAL), Extracorporeal Liver Assist Device (ELAD), transgenic pig perfusion
- •Patient receiving hemodialysis, hemofiltration or hemodiafiltration treatment
- •Intractable arterial hypotension (arterial systolic blood pressure equal to or below 70 mmHg) present or require inotropic drugs at baseline
- •Human Immunodeficiency Virus (HIV) positive patient
- •Active cancer
- •Pregnancy or breast-feeding
- •Surgery within 4 weeks prior to baseline, or unsolved surgical disease outside liver transplantation.
- •Patient included in another clinical trial within 4 weeks prior to baseline
- •Patient with organ or bone-marrow allograft
- •Absolute contra-indication to liver transplantation.
研究组 & 干预措施
ALF-5755
Experimental
干预措施: ALF-5755 (Drug)
Saline solution (0.9% NaCl)
Placebo Comparator
干预措施: Saline solution (0.9% NaCl) (Drug)
结局指标
主要结局
Rate of change of Prothrombin Rate initiation
时间窗: Over a period of 72 hours from baseline
次要结局
- Rate of change of Factor V (FV) plasma level(Over a period of 72 hours from baseline)
- Rate of change of international normalized ratio (INR)(Over a period of 72 hours from baseline)
- Rate of change of alanine transaminases (ALT) plasma level(Over a period of 72 hours from baseline)
- Rate of change of aspartate transaminases (AST) plasma level(Over a period of 72 hours from baseline)
- Change of Hepatic Encephalopathy Grade (HE grade)(Over a period of 72 hours from baseline)
研究者
研究点 (12)
Loading locations...
相似试验
Unknown
2 期
A Trial of Ribavirin in Patients With ACLF Due to Hepatitis E VirusAcute on Chronic Hepatic FailureHepatitis E InfectionLiver FailureNCT01698723All India Institute of Medical Sciences, New Delhi40
招募中
3 期
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisMetabolic Dysfunction Associated Steatohepatitis (MASH)Liver FibrosisNCT06632444Boehringer Ingelheim1,800
招募中
3 期
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisMetabolic Dysfunction Associated SteatohepatitisNCT06632457Boehringer Ingelheim1,590
已完成
不适用
Multicentric survey of acute on chronic liver failure in JapaAcute on chronic liver failureJPRN-UMIN000020304Health Labour Sciences Research Grant, Research on Measures for Intractable Diseases from the Ministry of Health, Labor and Welfare of Japan120
已完成
4 期
Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial PeritonitisHepatorenal SyndromeSpontaneous Bacterial PeritonitisCirrhosisNCT00359853Hospital Clinic of Barcelona70